Yuji Shibata, MD, PhD, on HER2-Mutant NSCLC: Mechanisms of Zongertinib Resistance

April 22, 2026

Yuji Shibata, MD, PhD, of The University of Texas MD Anderson Cancer Center, describes findings on the identification of novel HER2 mutations that mediate resistance to the tyrosine kinase inhibitor zongertinib among patients with non–small cell lung cancer (NSCLC); these data also indicated that sevabertinib may be effective against a subset of these genomic alterations (Abstract 7025). 

Related Content